Hodgkin Lymphoma, Version 2.2022 Featured Updates to the NCCN Guidelines

Richard T. Hoppe; Ranjana H. Advani; Weiyun Z. Ai; Richard F. Ambinder; Philippe Armand; Celeste M. Bello; Cecil M. Benitez; Weina Chen; Bouthaina Dabaja; Megan E. Daly; Leo I. Gordon; Neil Hansen; Alex F. Herrera; Ephraim P. Hochberg; Patrick B. Johnston; Mark S. Kaminski; Christopher R. Kelsey; Vaishalee P. Kenkre; Nadia Khan; Ryan C. Lynch; Kami Maddocks; Jonathan McConathy; Monika Metzger; David Morgan; Carolyn Mulroney; Sheeja T. Pullarkat; Rachel Rabinovitch; Karen C. Rosenspire; Stuart Seropian; Randa Tao; Pallawi Torka; Jane N. Winter; Joachim Yahalom; Joanna C. Yang; Jennifer L. Burns; Mallory Campbell; Hema Sundar

doi:10.6004/JNCCN.2022.0021

Hodgkin Lymphoma, Version 2.2022 Featured Updates to the NCCN Guidelines

Richard T. Hoppe, Ranjana H. Advani, Weiyun Z. Ai, Richard F. Ambinder, Philippe Armand, Celeste M. Bello, Cecil M. Benitez, Weina Chen, Bouthaina Dabaja, Megan E. Daly, Leo I. Gordon, Neil Hansen, Alex F. Herrera, Ephraim P. Hochberg, Patrick B. Johnston, Mark S. Kaminski, Christopher R. Kelsey, Vaishalee P. Kenkre, Nadia Khan, Ryan C. LynchKami Maddocks, Jonathan McConathy, Monika Metzger, David Morgan, Carolyn Mulroney, Sheeja T. Pullarkat, Rachel Rabinovitch, Karen C. Rosenspire, Stuart Seropian, Randa Tao, Pallawi Torka, Jane N. Winter, Joachim Yahalom, Joanna C. Yang, Jennifer L. Burns, Mallory Campbell, Hema Sundar

Research output: Contribution to journal › Article › peer-review

7 Scopus citations

Abstract

Hodgkin lymphoma (HL) is an uncommon malignancy of B-cell origin. Classical HL (cHL) and nodular lymphocyte-predominant HL are the 2 main types of HL. The cure rates for HL have increased so markedly with the advent of modern treatment options that overriding treatment considerations often relate to long-term toxicity. These NCCN Guidelines Insights discuss the recent updates to the NCCN Guidelines for HL focusing on (1) radiation therapy dose constraints in the management of patients with HL, and (2) the management of advanced-stage and relapsed or refractory cHL.

Original language	English
Pages (from-to)	322-334
Number of pages	13
Journal	JNCCN Journal of the National Comprehensive Cancer Network
Volume	20
Issue number	4
DOIs	https://doi.org/10.6004/JNCCN.2022.0021
State	Published - Apr 2022

Access to Document

10.6004/JNCCN.2022.0021

Cite this

Hoppe, R. T., Advani, R. H., Ai, W. Z., Ambinder, R. F., Armand, P., Bello, C. M., Benitez, C. M., Chen, W., Dabaja, B., Daly, M. E., Gordon, L. I., Hansen, N., Herrera, A. F., Hochberg, E. P., Johnston, P. B., Kaminski, M. S., Kelsey, C. R., Kenkre, V. P., Khan, N., ... Sundar, H. (2022). Hodgkin Lymphoma, Version 2.2022 Featured Updates to the NCCN Guidelines. JNCCN Journal of the National Comprehensive Cancer Network, 20(4), 322-334. https://doi.org/10.6004/JNCCN.2022.0021

@article{ddcfedbfe0594945afbc68c70afc64a1,

title = "Hodgkin Lymphoma, Version 2.2022 Featured Updates to the NCCN Guidelines",

abstract = "Hodgkin lymphoma (HL) is an uncommon malignancy of B-cell origin. Classical HL (cHL) and nodular lymphocyte-predominant HL are the 2 main types of HL. The cure rates for HL have increased so markedly with the advent of modern treatment options that overriding treatment considerations often relate to long-term toxicity. These NCCN Guidelines Insights discuss the recent updates to the NCCN Guidelines for HL focusing on (1) radiation therapy dose constraints in the management of patients with HL, and (2) the management of advanced-stage and relapsed or refractory cHL.",

author = "Hoppe, {Richard T.} and Advani, {Ranjana H.} and Ai, {Weiyun Z.} and Ambinder, {Richard F.} and Philippe Armand and Bello, {Celeste M.} and Benitez, {Cecil M.} and Weina Chen and Bouthaina Dabaja and Daly, {Megan E.} and Gordon, {Leo I.} and Neil Hansen and Herrera, {Alex F.} and Hochberg, {Ephraim P.} and Johnston, {Patrick B.} and Kaminski, {Mark S.} and Kelsey, {Christopher R.} and Kenkre, {Vaishalee P.} and Nadia Khan and Lynch, {Ryan C.} and Kami Maddocks and Jonathan McConathy and Monika Metzger and David Morgan and Carolyn Mulroney and Pullarkat, {Sheeja T.} and Rachel Rabinovitch and Rosenspire, {Karen C.} and Stuart Seropian and Randa Tao and Pallawi Torka and Winter, {Jane N.} and Joachim Yahalom and Yang, {Joanna C.} and Burns, {Jennifer L.} and Mallory Campbell and Hema Sundar",

note = "Funding Information: This activity is supported by educational grants from AstraZeneca; BeiGene; Exact Sciences; Gilead Sciences, Inc.; GlaxoSmithKline; Lantheus Medical Imaging Inc.; Novartis; Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; and Taiho Oncology, Inc. This activity is supported by an independent educational grant from Astellas. This activity is supported by an education grant from Astellas and Seagen Inc. This activity is supported by a medical education grant from Karyopharm{\textregistered} Therapeutics. This activity is supported through an Independent Medical Education grant from Merck & Co., Inc. Publisher Copyright: {\textcopyright} National Comprehensive Cancer Network, Inc. 2022. All rights reserved",

year = "2022",

month = apr,

doi = "10.6004/JNCCN.2022.0021",

language = "English",

volume = "20",

pages = "322--334",

journal = "JNCCN Journal of the National Comprehensive Cancer Network",

issn = "1540-1405",

number = "4",

}

Hoppe, RT, Advani, RH, Ai, WZ, Ambinder, RF, Armand, P, Bello, CM, Benitez, CM, Chen, W, Dabaja, B, Daly, ME, Gordon, LI, Hansen, N, Herrera, AF, Hochberg, EP, Johnston, PB, Kaminski, MS, Kelsey, CR, Kenkre, VP, Khan, N, Lynch, RC, Maddocks, K, McConathy, J, Metzger, M, Morgan, D, Mulroney, C, Pullarkat, ST, Rabinovitch, R, Rosenspire, KC, Seropian, S, Tao, R, Torka, P, Winter, JN, Yahalom, J, Yang, JC, Burns, JL, Campbell, M & Sundar, H 2022, 'Hodgkin Lymphoma, Version 2.2022 Featured Updates to the NCCN Guidelines', JNCCN Journal of the National Comprehensive Cancer Network, vol. 20, no. 4, pp. 322-334. https://doi.org/10.6004/JNCCN.2022.0021

TY - JOUR

T1 - Hodgkin Lymphoma, Version 2.2022 Featured Updates to the NCCN Guidelines

AU - Hoppe, Richard T.

AU - Advani, Ranjana H.

AU - Ai, Weiyun Z.

AU - Ambinder, Richard F.

AU - Armand, Philippe

AU - Bello, Celeste M.

AU - Benitez, Cecil M.

AU - Chen, Weina

AU - Dabaja, Bouthaina

AU - Daly, Megan E.

AU - Gordon, Leo I.

AU - Hansen, Neil

AU - Herrera, Alex F.

AU - Hochberg, Ephraim P.

AU - Johnston, Patrick B.

AU - Kaminski, Mark S.

AU - Kelsey, Christopher R.

AU - Kenkre, Vaishalee P.

AU - Khan, Nadia

AU - Lynch, Ryan C.

AU - Maddocks, Kami

AU - McConathy, Jonathan

AU - Metzger, Monika

AU - Morgan, David

AU - Mulroney, Carolyn

AU - Pullarkat, Sheeja T.

AU - Rabinovitch, Rachel

AU - Rosenspire, Karen C.

AU - Seropian, Stuart

AU - Tao, Randa

AU - Torka, Pallawi

AU - Winter, Jane N.

AU - Yahalom, Joachim

AU - Yang, Joanna C.

AU - Burns, Jennifer L.

AU - Campbell, Mallory

AU - Sundar, Hema

N1 - Funding Information: This activity is supported by educational grants from AstraZeneca; BeiGene; Exact Sciences; Gilead Sciences, Inc.; GlaxoSmithKline; Lantheus Medical Imaging Inc.; Novartis; Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; and Taiho Oncology, Inc. This activity is supported by an independent educational grant from Astellas. This activity is supported by an education grant from Astellas and Seagen Inc. This activity is supported by a medical education grant from Karyopharm® Therapeutics. This activity is supported through an Independent Medical Education grant from Merck & Co., Inc. Publisher Copyright: © National Comprehensive Cancer Network, Inc. 2022. All rights reserved

PY - 2022/4

Y1 - 2022/4

N2 - Hodgkin lymphoma (HL) is an uncommon malignancy of B-cell origin. Classical HL (cHL) and nodular lymphocyte-predominant HL are the 2 main types of HL. The cure rates for HL have increased so markedly with the advent of modern treatment options that overriding treatment considerations often relate to long-term toxicity. These NCCN Guidelines Insights discuss the recent updates to the NCCN Guidelines for HL focusing on (1) radiation therapy dose constraints in the management of patients with HL, and (2) the management of advanced-stage and relapsed or refractory cHL.

AB - Hodgkin lymphoma (HL) is an uncommon malignancy of B-cell origin. Classical HL (cHL) and nodular lymphocyte-predominant HL are the 2 main types of HL. The cure rates for HL have increased so markedly with the advent of modern treatment options that overriding treatment considerations often relate to long-term toxicity. These NCCN Guidelines Insights discuss the recent updates to the NCCN Guidelines for HL focusing on (1) radiation therapy dose constraints in the management of patients with HL, and (2) the management of advanced-stage and relapsed or refractory cHL.

UR - http://www.scopus.com/inward/record.url?scp=85129260330&partnerID=8YFLogxK

U2 - 10.6004/JNCCN.2022.0021

DO - 10.6004/JNCCN.2022.0021

M3 - Article

C2 - 35390768

AN - SCOPUS:85129260330

SN - 1540-1405

VL - 20

SP - 322

EP - 334

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

IS - 4

ER -

Hodgkin Lymphoma, Version 2.2022 Featured Updates to the NCCN Guidelines

Abstract

Access to Document

Other files and links

Fingerprint

Cite this